Stella Diagnostics Inc. (SLDX)
Stella Diagnostics Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Salt Lake City, UT, US. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $786,259. On trailing twelve-month figures it carries a trailing P/E of -0.58, a net margin of -255.8%. Its beta of -0.21 implies it has historically moved less than the broad market.
Stella Diagnostics Inc. is a molecular diagnostics firm primarily focused on advancing patient care strategies for individuals afflicted with severe esophageal disorders. The company's specialized clinical tests furnish physicians with crucial information regarding the molecular makeup of a patient's tissue, enabling them to ascertain if the disease is static, deteriorating, or undergoing malignant transformation. Additionally, Stella Diagnostics is engaged in the development of innovative diagnostic tools intended to provide healthcare professionals with enhanced molecular insights compared to conventional screening methods. The organization rebranded from its previous identity, JMP Properties, Inc., to Stella Diagnostics, Inc. in April 2021 and is based in Salt Lake City, Utah.
Stella Diagnostics Inc. is most often compared with the following Healthcare names: